Further outcome studies have demonstrated that high RRM1 expression (along with ERCC1 or PTEN up-regulation) is a determinant of optimal survival in early-stage non-small-cell lung cancer (NSCLC) [23]–[26]; however, other studies have shown seemingly conflicting results [27]–[29]. Here, RRM1 is linked to non-small cell lung carcinoma.